Clinical DataAtacicept demonstrated a statistically significant 42% reduction in urine protein creatinine ratio compared to placebo, providing convincing evidence to support its best-in-class potential.
Market PotentialThe IgAN market is considered large enough to support multiple products, offering growth potential for Vera Therapeutics.
Safety ProfileSafety data for VERA's treatment was favorable, with no serious infections reported, which addresses a common concern among doctors about long-term use of B cell modulators.